Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: Assay development, validation and application to a clinical study

被引:67
作者
Trivedi, RK [1 ]
Kallem, RR [1 ]
Mullangi, R [1 ]
Srinivas, NR [1 ]
机构
[1] Dr Reddys Labs Ltd, Discovery Res, Drug Metab & Pharmacokinet, Hyderabad 500049, Andhra Pradesh, India
关键词
rosuvastatin; fenofibric acid; method validation; LC-MS/MS; human plasma; pharmacokinetics;
D O I
10.1016/j.jpba.2005.05.005
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A simple, sensitive and specific LC-MS/MS method for simultaneous determination of rosuvastatin (RST) and fenofibric acid (FFA) was developed and validated with 500 mu L human plasma using carbamazepine as an internal standard (IS). The assay procedure involved a simple one-step liquid/liquid extraction of RST and FEA and IS from plasma into ethyl acetate. The organic layer was separated and evaporated under a gentle stream of nitrogen at 40 degrees C. The residue was reconstituted in the mobile phase and injected onto X-Terra MS C-18 column (4.6 mm x 50 mm, 5.0 mu m). Separation of RST, FFA and IS was achieved with a mobile phase consisting of 0.05 M formic acid: acetonitrile (45:55, v/v) at a flow rate of 0.40 ml/min. The API-3000 LC-MS/MS was operated under the multiple reaction-monitoring mode (MRM) using the electrospray ionization technique. Positive ion acquisition chromatographic run was used in the present method. Nominal retention times of RST, FFA and IS were 2.35, 4.70 and 2.32 min, respectively. Absolute recovery of RST, FFA and IS was 74, 61 and 69%, respectively. The lower limit of quantification (LLOQ) of RST and FFA was 1.00 ng/ml and 0.50 mu g/ml, respectively. Response function was established for the range of concentrations 1.00-50.0 ng/ml and 0.50-20.0 mu g/ml for RST and FFA, respectively, with a coefficient of determination (r) of 0.999 for both the compounds. The inter- and intra-day precision in the measurement of RST quality control (QC) samples 5, 15, 400 and 800 ng/ml, were in the range 8.93-9.37% relative standard deviation (R.S.D.) and 1.74-16.1% R.S.D., respectively. Similarly, the inter- and intra-day precision in the measurement of FFA quality control (QC) samples 0.5, 1.5, 8.0 and 15.0 mu g/ml, were in the range 9.78-11.6% relative standard deviation (R.S.D.) and 0.22-17.4% R.S.D., respectively. Accuracy in the measurement of QC samples for RST and FFA were in the range 88.1-108 and 87-115%, respectively, of the nominal values. RST and FFA were stable in the battery of stability studies, viz., bench-top, auto-sampler and freeze/thaw cycles. Stability of RST and FFA was established for I month at -80 degrees C. The application of the assay to a clinical study confirmed the utility of the assay. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:661 / 669
页数:9
相关论文
共 30 条
[1]   High-performance liquid chromatographic method for the determination of fenofibric acid and reduced fenofibric acid in human blood, plasma and urine [J].
Abe, S ;
Ono, K ;
Mogi, M ;
Hayashi, T .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1998, 118 (10) :447-455
[2]   Micronised fenofibrate - Review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia [J].
Adkins, JC ;
Faulds, D .
DRUGS, 1997, 54 (04) :615-633
[3]   Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial [J].
Brown, WV ;
Bays, HE ;
Hassman, DR ;
McKenney, J ;
Chitra, R ;
Hutchinson, H ;
Miller, E .
AMERICAN HEART JOURNAL, 2002, 144 (06) :1036-1043
[4]   Effects of fibrates on serum metabolic parameters [J].
Elisaf, M .
CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (05) :269-276
[5]   Micronized fenofibrate: A new fibric acid hypolipidemic agent [J].
Guay, DRP .
ANNALS OF PHARMACOTHERAPY, 1999, 33 (10) :1083-1103
[6]  
HOLDGATE GA, 2001, 14 INT S DRUGS AFF L
[7]   The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington Conference to the laboratory [J].
Hubert, P ;
Chiap, P ;
Crommen, J ;
Boulanger, B ;
Chapuzet, E ;
Mercier, N ;
Bervoas-Martin, S ;
Chevalier, P ;
Grandjean, D ;
Lagorce, P ;
Lallier, M ;
Laparra, MC ;
Laurentie, M ;
Nivet, JC .
ANALYTICA CHIMICA ACTA, 1999, 391 (02) :135-148
[8]   Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection [J].
Hull, Caroline K. ;
Penman, A.D. ;
Smith, C.K. ;
Martin, P.D. .
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 772 (02) :219-228
[9]   Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvalstaltin, and pravastatin across doses (STELLAR* trial) [J].
Jones, PH ;
Davidson, MH ;
Stein, EA ;
Bays, HE ;
McKenney, JM ;
Miller, E ;
Cain, VA ;
Blasetto, JW ;
STELLAR Study Grp .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (02) :152-160
[10]   Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia [J].
Kirchgassler, KU ;
Schmitz, H ;
Bach, G .
CLINICAL DRUG INVESTIGATION, 1998, 15 (03) :197-204